Obesity-related Kidney Disease

Primary Care - Clinics in Office Practice

Volumn 41, Issue 4, 2014, Pages 875-893

  Snyder, Samuel ^a   Turner, Gracie A ^b   Turner, Alan ^b  

^a NOVA SOUTHEASTERN UNIVERSITY   (United States)

^b NONE   (United States)

Author keywords

Hypertension; Inflammation; Insulin resistance; Kidney; Obesity

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; BARDOXOLONE METHYL; CHLOROQUINE; GLUCOSE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; PENTOXIFYLLINE; PYRIDOXAMINE; RIMONABANT; TETRAHYDROLIPSTATIN; CYTOKINE; GLUCOSE BLOOD LEVEL;

ALBUMINURIA; BARIATRIC SURGERY; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; CLINICAL EFFECTIVENESS; DIABETIC NEPHROPATHY; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE EXACERBATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; END STAGE RENAL DISEASE; GLOMERULOPATHY; GLUCOSE INTOLERANCE; HUMAN; HYPERTENSION; INCIDENCE; INSULIN TOLERANCE TEST; KIDNEY DISEASE; LIFESTYLE MODIFICATION; MICROALBUMINURIA; MOLECULAR PATHOLOGY; MORTALITY; NEPHRITIS; NONHUMAN; OBESITY; OBESITY RELATED GLOMERULOPATHY; OUTCOME ASSESSMENT; PROTEIN PROTEIN INTERACTION; REVIEW; RISK ASSESSMENT; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; ADIPOCYTE; ADRENERGIC SYSTEM; AGE; DYSLIPIDEMIAS; GENETIC PREDISPOSITION; GLUCOSE BLOOD LEVEL; HEALTH BEHAVIOR; INFLAMMATION; INSULIN RESISTANCE; LIFESTYLE; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; PREVALENCE; RENAL INSUFFICIENCY, CHRONIC; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SEX DIFFERENCE; UNITED STATES;

ADIPOCYTES; AGE FACTORS; BLOOD GLUCOSE; CYTOKINES; DYSLIPIDEMIAS; GENETIC PREDISPOSITION TO DISEASE; HEALTH BEHAVIOR; HUMANS; HYPERTENSION; INFLAMMATION; INSULIN RESISTANCE; LIFE STYLE; OBESITY; PREVALENCE; RENAL INSUFFICIENCY, CHRONIC; RENIN-ANGIOTENSIN SYSTEM; RISK FACTORS; SEX FACTORS; SYMPATHETIC NERVOUS SYSTEM; UNITED STATES;

EID: 84909989948     PISSN: 00954543     EISSN: 1558299X     Source Type: Journal    
DOI: 10.1016/j.pop.2014.08.008     Document Type: Review

References (99)

1. Freedman D. Obesity-United States, 1988-2008. MMWR Surveill Summ 2011, 60(1):73-77.
2. Centers for Disease Control and Prevention. Overweight and obesity: adult obesity facts. Available at: . Accessed on September 24, 2014. http://www.cdc.gov/obesity/data/adult.html.
3. United States Renal Data System. 2013 Atlas of CKD and ESRD [Chapter 1]. 2013. p. 44-50. Available at: . Accessed on September 24, 2014. http://www.usrds.org/adr.aspx.
4. Coresh J., Selvin E., Stevens W.A., et al. Prevalence of chronic kidney disease in the United States. JAMA 2007, 298(17):2038-2047.
5. Glassock R.J., Winearls C. An epidemic of chronic kidney disease: fact or fiction?. Nephrol Dial Transplant 2008, 23(4):1117-1121.
6. USRDS 2004 report. Available at: . Accessed on September 24, 2014. http://www.usrds.org/atlas04/aspx.
7. Zoccali C., Kramer A., Jager K.J. Epidemiology of CKD in Europe: an uncertain scenario. Nephrol Dial Transplant 2010, 25(6):1731-1733.
8. Hall J.E., Crook E.D., Jones D.W., et al. Mechanisms of obesity-associated cardiovascular and renal disease. Am J Med Sci 2002, 324(3):127-137.
9. Munkhaugen J., Lydersen S., Wideroe T.K., et al. Pre-hypertension, obesity and risk of kidney disease: 20-year follow-up of the HUNT-1 study in Norway. Am J Kidney Dis 2009, 54(4):638-646.
10. Maes H.H., Neale M.C., Eaves L.J. Genetic and environmental factors in relative body weight and human adiposity. Behav Genet 2008, 27:325-351.
11. Fawcett K.A., Barroso I. The genetics of obesity: FTO leads the way. Trends Genet 2010, 26:266-274.
12. Ramachandrappa S., Farooqi I.S. Genetic approaches to understanding human obesity. JClin Invest 2011, 121(6):2080-2086.
13. Elshamaa M.F., Sabty S.M., Bazaara H.M., et al. Genetic polymorphism of ACE and the angiotensin II type 1 receptor genes in children with chronic kidney disease. JInflamm 2011, 8(1):20.
14. Campbell C.Y., Fang B.F., Guo X., et al. Associations between genetic variants in the ACE, AGT, AGTR1 and AGTR2 genes and renal function in the Multiethnic Study of Atherosclerosis. Am J Nephrol 2010, 32(2):156-162.
15. Rudnicki M., Mayer G. Significance of genetic polymorphisms of the renin-angiotensin-aldosterone system in cardiovascular and renal disease. Pharmacogenomics 2009, 10(3):463-476.
16. Bell C.G., Meyre D., Petretto E., et al. No contribution of angiotensin-converting enzyme gene variants to severe obesity: a model for comprehensive case/controland quantitative cladistics analysis of ACE in human diseases. Eur J Hum Genet 2007, 15(3):320-327.
17. Su S.L., Lu K.C., Lin Y.F., et al. Gene polymorphisms of angiotensin-converting enzyme and angiotensin II type 1 receptor among chronic kidney disease patients in a Chinese population. JRenin Angiotensin Aldosterone Syst 2012, 13(1):148-154.
18. Gui-Yan Q.W., Yan-hua W., Qun X., et al. Associations between RAS gene polymorphisms, environmental factors and hypertension in Mongolian people. Eur J Epidemiol 2006, 21(4):287-292.
19. Mehri S., Jahjoub S., Hammami S., et al. Renin-angiotensin system polymorphisms in relation to hypertension status and obesity in a Tunisian population. Mol Biol Rep 2012, 39(4):4059-4065.
20. Siklar Z., Berberoglu M., Savas Erdeve S., et al. Contribution of clinical, metabolic and genetic factors on hypertension in obese children and adolescents. JPediatr Endocrinol Metab 2011, 24(1-2):21-24.
21. Mittal G., Gupta V., Haque S.F., et al. Effect of angiotensin converting enzyme gene I/D polymorphism in patients with metabolic syndrome in North Indian population. Chin Med J 2011, 124(1):45-48.
22. Fiatal S., Szigethy E., Szeles G., et al. Insertion/deletion polymorphism of angiotensin-1 converting enzyme is associated with metabolic syndrome in Hungarian adults. JRenin Angiotensin Aldosterone Syst 2011, 12(4):531-538.
23. Mondry A., Loh M., Liu P., et al. Polymorphisms of the insertion/deletion ACE and M235T AGT genes and hypertension: surprising new findings and met-analysis of date. BMC Nephrol 2005, 6:1.
24. Procopciuc L.M., Sitar-Taut A., Pop D., et al. Renin angiotensin system polymorphisms in patients with metabolic syndrome. Eur J Intern Med 2010, 21(5):414-418.
25. Thomas G.N., Tomlinson B., Chan J.C., et al. Renin-angiotensin system gene polymorphisms, blood pressure, dyslipidemia, and diabetes in Hong Kong Chinese: a significant association of the ACE insertion/deletions polymorphism with type 2 diabetes. Diabetes Care 2001, 24(2):356-361.
26. Toubal A., Treuter E., Clement K., et al. Genomic and epigenetic regulation of adipose tissue inflammation in obesity. Trends Endocrinol Metab 2013, 24(12):625-634.
27. Amarasekera M., Prescott S.L., Palmer D.J. Nutrition in early life, immune-programming and allergies: the role of epigenetics. Asian Pac J Allergy Immunol 2013, 31(3):175-182.
28. Tiwari S., Ndisang J.F. The role of obesity in cardiomyopathy and nephropathy. Curr Pharm Des 2014, 20(9):1409-1417.
29. Houde A.A., Hivert M.F., Bouchard L. Fetal epigenetic programming of adipokines. Adipocyte 2013, 2(1):41-46.
30. Dwivedi R.S., Herman J.G., McCaffrey T.A., et al. Beyond genetics: epigenetic code in chronic kidney disease. Kidney Int 2011, 79(1):23-32.
31. Martins D., Tareen N., Zadshir A., et al. Association of poverty with the prevalence of albuminuria: data from the third National Health and Nutrition Examination Survey (NHANES III). Am J Kidney Dis 2006, 47(6):965-971.
32. Ali M.K., Bullard K.M., Beckles G.L., et al. Household income and cardiovascular disease risks in U.S. children and young adults. Diabetes Care 2011, 34(9):1998-2004.
33. Lakkis J., Wier M. Pharmacological strategies for kidney function preservation: are there differences by ethnicity?. Adv Ren Replace Ther 2004, 11(1):24-40.
34. Egan B.M., Zhao Y., Axon R.N. US trends in prevalence, awareness, treatment, and control of hypertension, 1988-2008. JAMA 2010, 303(20):2043.
35. Wilson P.W., D'Agostino R.P., Sullivan L., et al. Overweight and obesity as determinants of cardiovascular risk: the Framingham experience. Arch Intern Med 2002, 162:1867-1872.
36. Kotchen T.A. Obesity-related hypertension: epidemiology, pathophysiology, and clinical management. Am J Hypertens 2010, 23(11):1170-1178.
37. Montani J.P., Antic V., Yang Z., et al. Pathways from obesity to hypertension: from the perspective of a vicious triangle. Int J Obes Relat Metab Disord 2002, 26(Suppl 2):s28-s38.
38. Aucott L., Rothnie H., McIntyre L., et al. Long-term weight loss from lifestyle intervention benefits blood pressure? A systematic review. Hypertension 2009, 54:756-762.
39. Whaley-Connell A.T., Sowers J.R., Stevens L.A., et al. CKD in the United States: Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES) 1999-2004. Am J Kidney Dis 2008, 51(4Suppl 2):S13.
40. Freedman B.I., Iskandar S.S., Appel R.G. The link between hypertension and nephrosclerosis. Am J Kidney Dis 1995, 25(2):207.
41. Martyn J., Kaneki M., Yasuhara S. Obesity-induced insulin resistance and hyperglycemia: etiological factors and molecular mechanisms. Anesthesiology 2008, 109(1):137-148.
42. Tomino Y., Hagiwara S., Gohda T. AGE-RAGE interaction and oxidative stress in obesity-related renal dysfunction. Kidney Int 2011, 80(2):133-135.
43. Sparvero L.J., Asafu-Adjei D., Kang R. RAGE (receptor for advanced glycation endproducts), RAGE ligands, and their role in cancer and inflammation. JTransl Med 2009, 7:17.
44. Tan A.L., Forbes J.M., Cooper M.E. AGE RAGE, and ROS in diabetic nephropathy. Semin Nephrol 2007, 27(2):130-143.
45. Gregor M., Hotamisligil G. Inflammatory mechanisms in obesity. Annu Rev Immunol 2011, 29:415-445.
46. Solinas G., Karin M. JNK1 and IKKbeta: molecular links between obesity and metabolic dysfunction. FASEB J 2010, 24(8):2596-2611.
47. Shi H., Kokoeva M.V., Inouye K., et al. TLR4 links innate immunity and fatty acid-induced insulin resistance. JClin Invest 2006, 116(11):739-745.
48. Marjolein V., Bouter L., McQuillan G., et al. Elevated C-reactive protein levels in overweight and obese adults. JAMA 1999, 282(22):2131-2135.
49. Fain J.N., Bahouth S.W., Madan A.K. TNFalpha release by the nonfat cells of human adipose tissue. Int J Obes Relat Metab Disord 2004, 28(4):616-622.
50. Nieto-Vasquez I., Fernandez-velido S., Kramer D.K., et al. Insulin resistance associated to obesity: the link TNF alpha. Arch Physiol Biochem 2008, 114(3):183-194.
51. Moreno J.A., Izquierdo M.C., Sanchez-Nino M.D., et al. The inflammatory cytokines TWEAK and TNFα reduce renal klotho expression through NFκB. JAm Soc Nephrol 2011, 22(7):1315-1325.
52. Rerolle J.P., Hertig A., Nguyen G., et al. Plasminogen activator inhibitor type 1 is a potential target in renal fibrogenesis. Kidney Int 2000, 58(5):1841-1850.
53. Matoba K., Kawanami D., Ishizawa S., et al. Rho-kinase mediates TNF-α-induced MCP-1 expression via p38 MAPK signaling pathway in mesangial cells. Biochem Biophys Res Commun 2010, 402(4):725-730.
54. Roytblat L., Rachinsky M., Fisher A., et al. Raised interleukin-6 levels in obese patients. Obes Res 2000, 8(9):673-675.
55. Serra A., Romero R., Lopez D., et al. Renal injury in the extremely obese patients with normal renal function. Kidney Int 2008, 73(8):947-955.
56. Wu Y., Liu Z., Xiang Z., et al. Obesity-related glomerulopathy: insights from gene expression profiles of the glomeruli derived from renal biopsy samples. Endocrinology 2006, 147(1):44-50.
57. Lord G.M., Matarese G., Howard J.K., et al. Leptin modulates the T-cell immune response and reverses starvation-induced immunosuppression. Nature 1998, 394(6696):897-901.
58. Agnello D., Meazza C., Rowan C.G., et al. Leptin causes body weight loss in the absence of invivo activities typical of cytokines of the IL-6 family. Am J Physiol 1998, 275(3 pt 2):R913-R919.
59. Engeli S., Feldpausch M., Gorzelniak K., et al. Association between adiponectin and mediators of inflammation in obese women. Diabetes 2003, 52(4):942-947.
60. Kambham N., Markowitz G.S., Valeri A.M., et al. Obesity-related glomerulopathy: an emerging epidemic. Kidney Int 2001, 59:1498-1509.
61. Tobar A., Ori Y., Benchetrit S., et al. Proximal tubular hypertrophy and enlarged glomerular and proximal tubular urinary space in obese subjects with proteinuria. PLoS One 2013, 8(9):e75547.
62. Amann K., Benz K. Structural renal changes in obesity and diabetes. Semin Nephrol 2013, 33(1):23-33.
63. D'Agati V., Schmidt A.M. RAGE and the pathogenesis of chronic kidney disease. Nat Rev Nephrol 2010, 6(6):352-360.
64. Shen Y.Y., Peake P.W., Charlesworth J.A. Adiponectin: its role in kidney disease. Nephrology (Carlton) 2008, 13:528-534.
65. Sharma K. The link between obesity and albuminuria: adiponectin and podocyte dysfunction. Kidney Int 2009, 76(2):145-148.
66. Chatzigeorgiou A., Karalis K.P., Bornsteint S.R., et al. Lymphocytes in obesity-related adipose tissue inflammation. Diabetologia 2012, 55(10):2583-2592.
67. Gotoh K., Inoue M., Masaki T., et al. Obesity-related chronic kidney disease is associated with spleen-derived IL-10. Nephrol Dial Transplant 2013, 28(5):1120-1130.
68. Harcourt B.E., Forbes J.M., Matthews V.B. Obesity-induced renal impairment is exacerbated in interleukin-6 knockout mice. Nephrology (Carlton) 2012, 17(3):257-262.
69. Darouich S., Goucha R., Jaafoura M.H., et al. Clinicopathological characteristics of obesity-associated focal segmental glomerulosclerosis. Ultrastruct Pathol 2011, 35(4):176-182.
70. Chen H.M., Liu Z.H., Zeng C.H., et al. Podocyte lesions in patients with obesity-related glomerulopathy. Am J Kidney Dis 2006, 48(5):772-779.
71. Tsuboi N., Utsunomiya Y., Kanzaki G., et al. Low glomerular density with glomerulomegaly in obesity-related glomerulopathy. Clin J Am Soc Nephrol 2012, 7(5):735-741.
72. Chen H.M., Li S.J., Chen H.P., et al. Obesity-related glomerulopathy in China: a case series of 90 patients. Am J Kidney Dis 2008, 52(1):58-65.
73. Shen W.W., Chen H.M., Chen H., et al. Obesity-related glomerulopathy: body mass index and proteinuria. Clin J Am Soc Nephrol 2010, 5(8):1401-1409.
74. Fowler S.M., Kon V., Ma L., et al. Obesity-related focal and segmental glomerulosclerosis: normalization of proteinuria in an adolescent after bariatric surgery. Pediatr Nephrol 2009, 24(4):851-855.
75. Tran H.A. Reversible obesity-related glomerulopathy following weight reduction. Med J Aust 2006, 184(7):367.
76. Engelen L., Stehouwer D.C., Schalkwijk C.G. Current therapeutic interventions in the glycation pathway: evidence from clinical studies. Diabetes Obes Metab 2013, 15(8):677-689.
77. Jun M., Venkataraman V., Razavian M., et al. Antioxidants for chronic kidney disease. Cochrane Database Syst Rev 2012, (10). CD008176.
78. Hirasawa Y., Matsui Y., Yamane K., et al. Pioglitazone improves obesity type diabetic nephropathy: relation to the mitigation of renal oxidative reaction. Exp Anim 2008, 57(5):423-432.
79. Shan D., Wu H.M., Yuan Q.Y., et al. Pentoxifylline for diabetic kidney disease. Cochrane Database Syst Rev 2012, (2). CD006800.
80. De Zeeuw D., Akizawa T., Audhya P., et al. Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease. NEngl J Med 2013, 369:2493-2503.
81. Hamden K., Mnafgui K., Amri Z., et al. Inhibition of key digestive enzymes related to diabetes and hyperlipidemia and protection of liver-kidney function by trigonelline in diabetic rats. Sci Pharm 2013, 81(1):233-246.
82. Ghule A.E., Jadhav S.S., Bodhankar S.L. Trigonelline ameliorates diabetic hypertensive nephropathy by suppression of oxidative stress in kidney and reduction in renal cell apoptosis and fibrosis in streptozotocin induced neonatal diabetic rats. Int Immunopharmacol 2012, 14(4):740-748.
83. Knight S.F., Yuan J., Roy S., et al. Simvastatin and tempol protect against endothelial dysfunction and renal injury in a model of obesity and hypertension. Am J Physiol Renal Physiol 2010, 298(1):F86-F94.
84. Whaley-Connell A., DeMarco V.G., Lastra G., et al. Insulin resistance, oxidative stress, and podocyte injury: role of rosuvastatin in modulation of filtration barrier injury. Am J Nephrol 2008, 28(1):67-75.
85. Wei J., Ma C., Wang X. Simvastatin inhibits tissue factor and plasminogen activator inhibitor-1 expression of glomerular mesangial cells in hypercholesterolemic rabbits. Biomed Res 2006, 27(4):149-155.
86. Osman M.M., Khalil A., Ahmed M.H. Chloroquine-induced nitric oxide: new treatment for an emerging epidemic of obesity-related glomerulopathy. Diabetes Technol Ther 2006, 8(6):691-692.
87. El Shazly A.H., Mahmoud A.M., Darwish N.S. Potential prophylactic role of aminoguanidine in diabetic retinopathy and nephropathy in experimental animals. Acta Pharm 2009, 59(1):67-73.
88. Abdel-Rahman E., Bolton W.K. Pimagedine: a novel therapy for diabetic nephropathy. Expert Opin Investig Drugs 2002, 11(4):565-574.
89. Elseweldy M.M., Elswefy S.E., Younis N.N., et al. Pyridoxamine, an inhibitor of protein glycation, in relation to microalbuminuria and proinflammatory cytokines in experimental diabetic nephropathy. Exp Biol Med 2013, 238(8):881-888.
90. Nakamura S., Li H., Adijiang A. Pyridoxal phosphate prevents progression of diabetic nephropathy. Nephrol Dial Transplant 2007, 22(8):2165-2174.
91. Waston A.M., Gray S.P., Jiaze L., et al. Alagebrium reduces glomerular fibrogenesis and inflammation beyond preventing RAGE activation in diabetic apolipoprotein E knockout mice. Diabetes 2012, 61(8):2105-2113.
92. Park J., Kwon M.K., Huh J.Y., et al. Renoprotective antioxidant effect of alagebrium in experimental diabetes. Nephrol Dial Transplant 2011, 26(11):3473-3484.
93. Ahmed M.H. Rimonabant as a potential new treatment for an emerging epidemic of obesity-related glomerulopathy?. Expert Opin Emerg Drugs 2006, 11(4):563-565.
94. Coutinho A.K., Glancey G.R. Orlistat, an under-recognised cause of progressive renal impairment. Nephrol Dial Transplant 2013, 28(Suppl 4):172-174. iv.
95. Veerman J.L., Barendregt J.J., Forster M., et al. Cost-effectiveness of pharmacotherapy to reduce obesity. PLoS One 2011, 6(10):e26051.
96. Serpa Neto A., Bianco Rossi F.M., Dal Moro Amarante R., et al. Effect of weight loss after Roux-en-Y gastric bypass on renal function and blood pressure in morbidly obese patients. JNephrol 2009, 22(5):637-646.
97. Huan Y., Tomaszewski J.E., Cohen D.L. Resolution of nephrotic syndrome after successful bariatric surgery in patient with biopsy proven FSGS. Clin Nephrol 2009, 71(1):69-73.
98. Alexander J.W., Goodman H.R., Hawver L.R., et al. Improvement and stabilization of chronic kidney disease after gastric bypass. Surg Obes Relat Dis 2009, 5(2):237-241.
99. Fenske W., Athanasiou T., Harling L., et al. Obesity-related cardiorenal disease: the benefits of bariatric surgery. Nat Rev Nephrol 2013, 9:539-551.